Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) announced a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80, effective with the dividend payable on April 20, 2026 to shareholders of record on April 6, 2026.
The change raises the annual cash dividend to $3.44 per share and follows 15 consecutive years of dividend increases. The Board also authorized a $1 billion increase in the share repurchase program, added to approximately $0.4 billion available as of December 31, 2025.
Positive
- Quarterly dividend increased by 7.5% to $0.86 per share
- Annual cash dividend raised to $3.44 per share
- Board authorized an incremental $1.0 billion in share repurchases
Negative
- Higher dividend raises the company's ongoing cash payout obligation to $3.44 annually per share
- Share repurchase authorization used up to $1.4 billion available may reduce near-term liquidity optionality
News Market Reaction – DGX
In the Feb 10 session, DGX gained 7.37%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.8% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Product launch | Positive | -1.1% | Launch of ultrasensitive MRD blood test for multiple myeloma. |
| Jan 21 | Corporate recognition | Positive | -2.3% | Named to Fortune’s 2026 World’s Most Admired Companies list. |
| Jan 15 | Leadership change | Positive | +1.9% | Appointment of CEO-elect at Sonora Quest with planned leadership transition. |
| Jan 08 | Earnings timing | Neutral | -0.2% | Announcement of date and logistics for Q4 and full-year 2025 results. |
| Jan 06 | Clinical data | Positive | +4.0% | Upcoming ASCO GI data presentations using Haystack MRD ctDNA test. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive announcements have produced mixed reactions, with some innovations and recognition coinciding with short-term share price declines, while other clinical and corporate updates aligned with gains.
Over the past weeks, Quest Diagnostics reported several developments. On Jan 6, data on its Haystack MRD test tied to ASCO GI presentations saw a 4.02% gain. A CEO-elect announcement at Sonora Quest on Jan 15 coincided with a 1.87% rise. However, recognition in Fortune’s “Most Admired Companies” on Jan 21 and the Feb 2 launch of a myeloma MRD test were followed by -2.28% and -1.09% moves, respectively. The new dividend increase and buyback fit within this ongoing capital allocation and innovation narrative.
Key Terms
AI-generated analysis. How Rhea-AI works. Not financial advice.
Additionally, the Board of Directors has increased the Company's share repurchase authorization by
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-increases-dividend-7-5-to-0-86-per-quarter-marking-15-consecutive-years-of-dividend-increases-announces-1-billion-increase-in-share-repurchase-authorization-302683204.html
SOURCE Quest Diagnostics